4//SEC Filing
BARR PHARMACEUTICALS INC 4
Accession 0001209191-08-067436
CIK 0000010081operating
Filed
Dec 28, 7:00 PM ET
Accepted
Dec 29, 11:17 AM ET
Size
27.9 KB
Accession
0001209191-08-067436
Insider Transaction Report
Form 4
Sawyer Timothy
Executive VP
Transactions
- Disposition to Issuer
Stock Appreciation Rights
2008-12-23−18,000→ 0 totalExercise: $46.99Exp: 2015-07-27→ Common Stock (18,000 underlying) - Disposition to Issuer
Stock Option
2008-12-23−2→ 0 totalExercise: $11.06From: 2001-08-11Exp: 2009-08-11→ Common Stock (2 underlying) - Disposition to Issuer
Stock Options
2008-12-23−22,500→ 0 totalExercise: $43.34Exp: 2013-07-30→ Common Stock (22,500 underlying) - Disposition to Issuer
Stock Appreciation Rights
2008-12-23−15,000→ 0 totalExercise: $48.80From: 2008-11-11Exp: 2016-07-26→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Options
2008-12-23−11,278→ 0 totalExercise: $26.58Exp: 2012-08-07→ Common Stock (11,278 underlying) - Disposition to Issuer
Stock Appreciation Rights
2008-12-23−24,000→ 0 totalExercise: $49.22From: 2008-11-11Exp: 2018-03-04→ Common Stock (24,000 underlying) - Disposition to Issuer
Stock Options
2008-12-23−2,707→ 0 totalExercise: $36.33From: 2004-08-08Exp: 2011-08-08→ Common Stock (2,707 underlying) - Disposition to Issuer
Stock Options
2008-12-23−10,000→ 0 totalExercise: $35.01Exp: 2014-08-04→ Common Stock (10,000 underlying) - Disposition to Issuer
Common Stock
2008-12-23−652.152→ 0 total - Disposition to Issuer
Stock Appreciation Rights
2008-12-23−45,000→ 0 totalExercise: $49.49From: 2008-11-11Exp: 2017-03-07→ Common Stock (45,000 underlying)
Footnotes (11)
- [F1]Disposed of pursuant to a merger agreement between Issuer and Teva Pharmaceutical Industries Ltd. in exchange for 409 shares of Teva Common Stock having a market value of $41.82 per share on the effective date of the merger and cash in the amount of $26,020.86.
- [F10]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $765,450, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.49 per share.
- [F11]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $414,720, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $49.22 per share.
- [F2]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $110.88, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $11.06 per share.
- [F3]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $81,679.12, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $36.3267 per share.
- [F4]Option vested equally over a 3 year period from grant date
- [F5]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $450,217.76, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $26.58 per share.
- [F6]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $521,100, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $43.34 per share.
- [F7]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $314,900, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $35.01 per share.
- [F8]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $351,180, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $46.99 per share.
- [F9]These options were cancelled pursuant to the merger agreement between the Issuer and Teva in exchange for the aggregate cash payment of $265,500, which represents the difference between the $66.50 per share price specified in the merger agreement and the option price of $48.80 per share.
Documents
Issuer
BARR PHARMACEUTICALS INC
CIK 0000010081
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000010081
Filing Metadata
- Form type
- 4
- Filed
- Dec 28, 7:00 PM ET
- Accepted
- Dec 29, 11:17 AM ET
- Size
- 27.9 KB